3,382 Shares in Boston Scientific Corporation (NYSE:BSX) Purchased by Abel Hall LLC

Abel Hall LLC bought a new position in Boston Scientific Corporation (NYSE:BSX - Free Report) during the first quarter, according to its most recent filing with the SEC. The firm bought 3,382 shares of the medical equipment provider's stock, valued at approximately $341,000.

Other large investors also recently modified their holdings of the company. HM Payson & Co. raised its position in Boston Scientific by 1.4% in the 1st quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider's stock valued at $694,000 after buying an additional 98 shares during the last quarter. Baldwin Investment Management LLC increased its holdings in Boston Scientific by 1.2% in the 4th quarter. Baldwin Investment Management LLC now owns 8,740 shares of the medical equipment provider's stock worth $781,000 after acquiring an additional 102 shares during the last quarter. Park Square Financial Group LLC increased its holdings in Boston Scientific by 5.2% in the 1st quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider's stock worth $208,000 after acquiring an additional 103 shares during the last quarter. Evergreen Capital Management LLC increased its holdings in Boston Scientific by 1.7% in the 4th quarter. Evergreen Capital Management LLC now owns 6,331 shares of the medical equipment provider's stock worth $565,000 after acquiring an additional 106 shares during the last quarter. Finally, Forum Financial Management LP increased its holdings in Boston Scientific by 0.8% in the 1st quarter. Forum Financial Management LP now owns 13,448 shares of the medical equipment provider's stock worth $1,357,000 after acquiring an additional 112 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

BSX has been the subject of several recent research reports. Evercore ISI lifted their price objective on Boston Scientific from $110.00 to $112.00 and gave the stock an "outperform" rating in a report on Thursday, April 24th. Oppenheimer lifted their price objective on Boston Scientific from $110.00 to $118.00 and gave the stock a "market perform" rating in a report on Thursday. Needham & Company LLC reissued a "buy" rating and issued a $115.00 price objective on shares of Boston Scientific in a report on Wednesday, May 28th. Erste Group Bank raised Boston Scientific to a "strong-buy" rating in a report on Thursday, May 8th. Finally, BTIG Research restated a "buy" rating and issued a $124.00 target price on shares of Boston Scientific in a research note on Wednesday, April 23rd. Two research analysts have rated the stock with a hold rating, twenty-two have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Boston Scientific currently has a consensus rating of "Buy" and a consensus target price of $117.50.

Boston Scientific Trading Down 1.5%

Shares of BSX traded down $1.58 during mid-day trading on Thursday, hitting $106.18. 10,261,534 shares of the company's stock traded hands, compared to its average volume of 7,588,135. The company has a quick ratio of 0.88, a current ratio of 1.45 and a debt-to-equity ratio of 0.47. Boston Scientific Corporation has a 1 year low of $71.88 and a 1 year high of $108.94. The firm has a market capitalization of $157.09 billion, a P/E ratio of 38.08, a PEG ratio of 3.06 and a beta of 0.68. The business's 50-day moving average price is $103.55 and its 200-day moving average price is $101.31.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.39% and a net margin of 13.55%. The company had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same period in the previous year, the company posted $0.62 earnings per share. The firm's revenue was up 22.8% on a year-over-year basis. As a group, sell-side analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Michael F. Mahoney sold 164,443 shares of the company's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $103.69, for a total transaction of $17,051,094.67. Following the transaction, the chief executive officer directly owned 1,476,882 shares of the company's stock, valued at $153,137,894.58. This represents a 10.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP John Bradley Sorenson sold 4,572 shares of the company's stock in a transaction on Monday, May 5th. The shares were sold at an average price of $104.54, for a total value of $477,956.88. Following the transaction, the executive vice president directly owned 18,705 shares in the company, valued at approximately $1,955,420.70. The trade was a 19.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 457,144 shares of company stock valued at $47,296,288. 0.50% of the stock is owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.